{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Post-transplant+Abatacept", "query": { "intervention": "Post-transplant Abatacept" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 46, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Post-transplant+Abatacept&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T16:23:56.141Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06008808", "title": "Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graft Vs Host Disease", "Graft-versus-host-disease", "Graft Versus Host Disease" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2024-05-07", "completion_date": "2027-11-27", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-28T16:23:56.141Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06008808" }, { "nct_id": "NCT04066114", "title": "Treg Modulation With CD28 and IL-6 Receptor Antagonists", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Living-Donor Kidney Transplant", "Kidney Transplant Recipients" ], "interventions": [ { "name": "lulizumab pegol", "type": "BIOLOGICAL" }, { "name": "antithymocyte globulin (rabbit)", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "tocilizumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "belatacept", "type": "BIOLOGICAL" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "mycophenolic acid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2019-12-11", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-28T16:23:56.141Z", "location_count": 7, "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04066114" }, { "nct_id": "NCT01790594", "title": "Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Simultaneous Kidney and Pancreas Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "Anti-thymocyte Globulin (Rabbit)", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 46, "start_date": "2013-02", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-28T16:23:56.141Z", "location_count": 5, "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01790594" }, { "nct_id": "NCT00276250", "title": "Islet Transplantation Using Abatacept", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Efalizumab", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Belatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 5, "start_date": "2005-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-07-27", "last_synced_at": "2026-09-28T16:23:56.141Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00276250" }, { "nct_id": "NCT06055608", "title": "Advancing Transplantation Outcomes in Children", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Belatacept", "type": "BIOLOGICAL" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus (Group1)", "type": "DRUG" }, { "name": "Anti-Thymocyte Globulin (ATG)", "type": "DRUG" }, { "name": "Tacrolimus (Group 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "13 Years to 20 Years" }, "enrollment_count": 200, "start_date": "2024-05-22", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-28T16:23:56.141Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06055608" }, { "nct_id": "NCT04477629", "title": "Belatacept in De Novo Heart Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Corticosteroid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 12, "start_date": "2020-08-06", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-09-28T16:23:56.141Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04477629" }, { "nct_id": "NCT01875224", "title": "Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "New Onset Diabetes After Transplant", "Kidney Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2013-08", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2013-06-11", "last_synced_at": "2026-09-28T16:23:56.141Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01875224" }, { "nct_id": "NCT07675174", "title": "Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "GVHD - Graft-Versus-Host Disease" ], "interventions": [ { "name": "Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2026-07-01", "completion_date": "2032-07-01", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-28T16:23:56.141Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07675174" }, { "nct_id": "NCT03504241", "title": "Tolerance by Engaging Antigen During Cellular Homeostasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Transplantation", "Renal Transplantation", "Renal Transplant Recipient" ], "interventions": [ { "name": "Donor-derived Mesenchymal Stromal Cells", "type": "BIOLOGICAL" }, { "name": "alemtuzumab", "type": "DRUG" }, { "name": "belatacept", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "mycophenolate acid", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 8, "start_date": "2018-07-30", "completion_date": "2025-09-16", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-28T16:23:56.141Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03504241" }, { "nct_id": "NCT06478017", "title": "Belatacept in Heart Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Transplant" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil/Sodium", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "71 Years", "sex": "ALL", "summary": "18 Years to 71 Years" }, "enrollment_count": 66, "start_date": "2025-01-29", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-28T16:23:56.141Z", "location_count": 6, "location_summary": "Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06478017" } ] }